ObsEva Receives Clearance from US FDA to Initiate Phase 2b Study EDELWEISS with OBE2109, a Potentially Best-in-Class Oral GnRH ...
GENEVA, July 6, 2016 (GLOBE NEWSWIRE) -- ObsEva, a Swiss biopharmaceutical company innovating women's reproductive health and pregnancy therapeutics, today announced that its Investigational New Drug (IND) application to the U.S. Food and Drug …